media – Page 195 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

New Liquid Biopsy Approach Improves Blood Tests’ Ability to Detect Circulating Tumor DNA

Tumors continuously release DNA from dying cells into the bloodstream, which is rapidly broken down. This makes it difficult for existing blood tests to detect the minute amounts of tumor DNA present at any given time. Now, a team of researchers has developed an innovative method to amplify the detection of tumor DNA in blood, a breakthrough that could enhance cancer diagnosis and treatment monitoring. Researchers at Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) have created “priming agents,” injectable molecules that temporarily slow the clearance of circulating tumor DNA from the bloodstream. These priming agents target the body’s two main mechanisms for removing circulating DNA: DNases, enzymes that break down DNA in the blood, and macrophages, immune cells that absorb cell-free DNA during blood filtration through the liver. The researchers developed two types of priming agents. The first is a monoclonal antibody that attaches to circulating DNA, shielding ...
- Source: https://www.labmedica.com/molecular-diagnostics/articles/294799968/new-liquid-biopsy-approach-improves-blood-tests-ability-to-detect-circulating-tumor-dna.html
- 135
- January 24, 2024
SinoCellTech SCTC21C Injection Receives Drug Clinical Trial Approval

SinoCellTech (hereinafter referred to as the “Company”) has received the Notice of Approval for Drug Clinical Trial issued by the State Drug Administration (hereinafter referred to as the “SDA”), agreeing that the Company’s self-developed product, SCTC21C Injection, could be used in clinical trials for the treatment of CD38+ hematologic malignancies. (hereinafter referred to as the “Company”) received a Notice of Approval for Clinical Trial of Drugs from the State Drug Administration (hereinafter referred to as the “SDA”), agreeing to carry out a clinical trial of the Company’s self-developed product, SCTC21C Injection, for the treatment of CD38+ hematologic malignancies. As there are many unpredictable factors in the process of clinical trial of drugs, the results of clinical trial, review and approval as well as the timing are subject to a certain degree of uncertainty, we respectfully request investors to make decisions cautiously and pay attention to the prevention of investment ...
- Source: https://mp.weixin.qq.com/s/kGdV5hX3S2pN8s5z6zQhSA
- 195
- January 24, 2024
Bristol Myers shows power of Opdivo-Yervoy combo in first-line colorectal cancer subset

More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnosed patients. But another approval may have to wait. The dual immunotherapy combo of Opdivo and Yervoy cut the risk of disease progression or death by 79% compared with chemotherapy—with or without targeted therapies—in patients newly diagnosed with metastatic colorectal cancer that was microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR). Investigators shared the results, from the CheckMate 8HW study, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. After about two years of median follow-up, 72% of patients who received the anti-PD-1/CTLA-4 combo were alive without disease progression, versus 14% in the control group. The results “have potentially practice-changing implications” for previously untreated MSI-H/dMMR metastatic colorectal cancer, lead study author Thierry Andre, M.D., from the Sorbonne Université in Paris, said in a ...
- Source: https://www.fiercepharma.com/pharma/bristol-myers-shows-opdivo-yervoy-dual-immunotherapys-power-first-line-colorectal-cancer
- 103
- January 24, 2024
Data from 11 studies of CHIATAI TIANQING’s class 1 innovator anilotinib, pembrolizumab, and bemosulbemab unveiled

The American Society of Clinical Oncology Gastrointestinal Oncology Symposium (ASCO GI) 2024 has been successfully concluded. CHIATAI TIANQING Pharmaceutical Group’s Class 1 innovative drugs Anrotinib (small molecule multi-targeted receptor tyrosine kinase inhibitor), Paianprilizumab (PD-1 inhibitor) and Behmosubaisumab (TQB2450, PD-L1 inhibitor) have been selected to be presented at the poster session this time with a total of 11 studies, which are related to the field of GI tumors with liver metastasis, esophageal cancer, hepatocellular carcinoma, tumors of the biliary tract system, and colorectal cancer. ALTER-G-001 is a multi-cohort, multi-center phase II study, and updated results from Cohort A were presented at this ASCO GI meeting. Patients in Cohort A were treated with 6 cycles (3 weeks each) of anilotinib (12 mg, po, qd, d1-14, q3w) + oxaliplatin (130 mg/m2, iv, d1, q3w) + capecitabine (850 mg/m2, po, bid, d1-14, q3w), and if liver metastases were not converted to resectable on ...
- Source: drugdu
- 162
- January 24, 2024
Gilead Drug Fails Pivotal Lung Cancer Study, But Still Might Have Path Forward

Gilead Sciences said even though Trodelvy missed the main goal of its Phase 3 test in non-small cell lung cancer, the drug’s preliminary results show numerical improvement in patients whose disease did not respond to prior treatment with immunotherapy. The company plans to discuss with regulators a possible path forward in these patients. By FRANK VINLUAN Sales for Gilead Sciences cancer drug Trodelvy are growing, but the company is counting on additional approvals to boost the product to blockbuster status and justify the premium price it paid to acquire the therapy. The drug’s failure in a pivotal lung cancer study is a setback to that strategy. Treatment with Trodelvy, an antibody drug conjugate (ADC), fell short of a Phase 3 study’s main goal of showing statistically significant improvement in overall survival in patients with advanced cases of non-small cell lung cancer (NSCLC), Gilead announced Monday. Nevertheless, the company pointed to numerical ...
- Source: https://medcitynews.com/author/fvinluan/
- 193
- January 24, 2024
NHS catch up campaign launched for missed MMR vaccines

Approximately one in five children will be hospitalised to treat measles The NHS has announced the launch of its new catch up campaign to get millions of children booked in for their missed measles, mumps and rubella (MMR) vaccine. The new campaign aligns with the health services efforts to protect children from becoming seriously ill as cases of measles rise across the UK. MMR are highly infectious illnesses that can lead to blindness, deafness and swelling of the brain. Considered more infectious than COVID-19, NHS analysis has shown that one infected child in a classroom can infect up to nine other unvaccinated children. In total, more than 3.4 million children under the age of 16 are currently unprotected and are at risk of catching MMR. The new campaign will assure that all parents of children from the age of six to 11 years are contacted to book an appointment with ...
- Source: https://pharmatimes.com/news/nhs-catch-up-campaign-launched-for-missed-mmr-vaccines/
- 101
- January 24, 2024
Lilly’s Jaypirca tipped to capture 60% of BTK leukemia market, leaving AstraZeneca, BeiGene in the dust

Eli Lilly’s attempt to wrestle a leukemia market from companies including AbbVie, AstraZeneca, BeiGene and Johnson & Johnson has analysts purring, with the GlobalData team tipping the drugmaker to capture 60% of demand and deliver $3 billion in annual sales. The GlobalData report covers the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL). Pharmacyclics, now part of AbbVie, and J&J created the market with Imbruvica but now face a sea of threats, with the Inflation Reduction Act, increased competition and the looming prospect of generics pointing to a downward trajectory. AstraZeneca’s Calquence began challenging Imbruvica for the CLL market in 2019 and BeiGene’s Brukinsa joined the party last year. But the GlobalData analysts expect Lilly to come from behind to become the dominant force in CLL in the coming years. Lilly won accelerated FDA approval for Jaypirca in CLL last month. While the drugmaker, which acquired Jaypirca in its $8 billion ...
- Source: https://www.pharma.com/marketing/lillys-jaypirca-tipped-capture-60-btk-leukemia-market-leaving-astrazeneca-beigene-dust
- 159
- January 24, 2024
Opdivo Plus Yervoy Reduces the Risk of Colorectal Cancer Disease Progression or Death by 79% Versus Chemotherapy

Opdivo plus Yervoy shows promise in treating patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer. Image Credit: Adobe Stock Images/Crystal light The combination of Bristol Myers Squibb’s Opdivo (nivolumab) with Yervoy (ipilimumab) showed significant improvements in progression-free survival (PFS) as a first-line treatment for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)in the Phase III CheckMate -8HW trial. The combination produced a 79% reduction in the risk of disease progression or death compared to chemotherapy, according to the trial. “Patients with MSI-H/dMMR metastatic colorectal cancer are less likely to benefit from chemotherapy,” said Thierry Andre, MD, head of the medical oncology department, Sorbonne University, Hospital Saint-Antoine, Paris, France, in a press release. “An impressive improvement in PFS and sustained benefit beginning at three months was observed with nivolumab plus ipilimumab versus chemotherapy in this trial. These results demonstrate ...
- Source: https://www.pharmexec.com/authors/don-tracy-associate-editor
- 77
- January 24, 2024
Immune checkpoint inhibitor target found to promote skin cancer growth

Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer. But PD-1 functions can vary between different cell and cancer types, either promoting or suppressing disease progression. Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer, responds well to immune checkpoint inhibitor therapy. However, it was previously unknown if MCC cells express PD-1 themselves, and unclear how exactly cancer cell-intrinsic PD-1 contributes to tumor growth. A study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, identified a new mechanism through which PD-1 promotes MCC progression. Through a series of experiments, the researchers demonstrated PD-1 expression on MCC cells in preclinical models and patient tumor samples. They found that MCC-PD-1 receptor binding to its ligands ...
- Source: drugdu
- 99
- January 23, 2024
RecA protein skips “unwinding” step in DNA repair

Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a dangling single-strand end into intact double strands, and repairing the break based on the undamaged sequence. They discovered that RecA finds where to put the single strand into the double helix without unwinding it by even a single turn. Their findings promise new directions in cancer research. Homologous recombination (HR) is a ubiquitous biochemical process shared across all living things, including animals, plants, fungi, and bacteria. As we go about our daily lives, our DNA is subjected to all kinds of environmental and internal stress, some of which can lead to breakage of both strands in the double helix. This can be disastrous, and lead to imminent cell death. Luckily, processes like HR are continuously repairing this damage. During HR, one of the two exposed ...
- Source: drugdu
- 183
- January 23, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.